Form 4: Northwest Biotherapeutics Director Navid Malik Sells Stock Options

Director Navid Malik of Northwest Biotherapeutics sold 657,895 common stock options to former director Jerry Jasinowski on July 26, 2024.

Summary

• Navid Malik, a director of Northwest Biotherapeutics, Inc. (NWBO), filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on July 26, 2024.
• Mr. Malik sold 657,895 common stock options to Jerry Jasinowski, a former director of Northwest Biotherapeutics, Inc.
• The exercise price of the stock options is $0.23.
• Following the transaction, Mr. Malik directly owns 23,339,393 shares of common stock.
• The options were originally granted on May 28, 2018, and expire on May 28, 2028.
• The price of the derivative security was $0.38.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a transaction. It doesn't inherently indicate positive or negative news about the company's performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders of a publicly traded company buy or sell the company's securities. This filing indicates a change in beneficial ownership by a director of Northwest Biotherapeutics.

Related Party Transactions

• The sale of stock options from director Navid Malik to former director Jerry Jasinowski constitutes a related party transaction.

Stakeholder Impact

• The sale of options by a director could be perceived differently by shareholders; some might see it as a lack of confidence, while others might view it as a personal financial decision.

Key Dates